APELLIS PHARMACEUTICALS INC (APLS)

US03753U1060 - Common Stock

47.93  -2 (-4.01%)

After market: 47.93 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
66.6M
-73.42%		75.4M
13.21%		396.591M
425.98%		812.77M
104.94%
EBITDA
YoY % growth
-534.92M
-151.07%		-593.05M
-10.87%		-515.337M
13.10%		-108.773M
78.89%
EBIT
YoY % growth
-536.3M
-150.96%		-594.6M
-10.87%		-517.121M
13.03%		-140.212M
72.89%
Operating Margin
-805.26%-788.59%-130.39%-17.25%
EPS
YoY % growth
-8.93
-89.19%		-6.13
31.35%		-4.48
26.92%		-1.23
72.60%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.56
64.37%
Revenue
Q2Q % growth		165.02M
268.35%
EBITDA
Q2Q % growth		-65.93M
EBIT
Q2Q % growth		-63.062M
63.99%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.73
51.33%		-0.70-0.03-4.28%
Q3 2023
Q2Q % growth		 -1.17
33.14%		-0.87-0.30-34.09%
Q2 2023
Q2Q % growth		 -1.02
30.14%		-1.350.3324.40%
Q1 2023
Q2Q % growth		 -1.56
-9.86%		-1.49-0.07-4.46%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 146.377M
544.83%		146.47M-93K-0.06%
Q3 2023
Q2Q % growth		 110.4M
399.55%		101.04M9.36M9.26%
Q2 2023
Q2Q % growth		 95M
482.82%		71.657M23.343M32.58%
Q1 2023
Q2Q % growth		 44.8M
211.11%		26.625M18.175M68.26%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-0.42% 2.81% -7.75% 28.26%
Revenue0% 5.05% 1.41% 24.14%